LillyDirect self-pay prices for Zepbound pens and vials match at $299 to $449

On September 2, 2026, a pricing review recorded that LillyDirect self-pay prices for Zepbound (tirzepatide) are now identical whether a patient buys a KwikPen or a single-dose vial: $299 a month at 2.5 mg, $399 at 5 mg, and $449 at 7.5 mg and above when the prescription is refilled within 45 days ^[1]. The regular prices for those same fills run from $599 to $1,049 ^[1].

The same review priced Foundayo (orforglipron), Lilly's oral GLP-1, at $149 a month at 0.8 mg and, temporarily through December 31, 2026, at 2.5 mg; $199 at 5.5 mg; and $299 at the three top doses, 9, 14.5 and 17.2 mg ^[1]. The 14.5 mg and 17.2 mg prices require a refill within 45 days, otherwise they run $349 ^[1]. Foundayo's list price is $649 ^[1].

TrumpRx.gov, the federal site that links to manufacturers' own cash-pay programs rather than selling drugs itself, listed four GLP-1s on September 2: the Wegovy pen, the Wegovy pill, Ozempic and Zepbound ^[1]. Foundayo and Mounjaro did not appear on the site that day, and the Zepbound page routes buyers to LillyDirect ^[1]. Listed prices were $199 for the Wegovy pen for new patients' first two fills, $149 for the Wegovy pill at 1.5 mg, $199 for Ozempic and $299 for Zepbound vials ^[1]. Novo Nordisk's $199 Wegovy starter offer now runs through December 31, 2026, after which the price is $349, or $399 for Wegovy HD 7.2 mg ^[1]. The Wegovy pill's 4 mg dose moved from $149 to $199 on September 1 ^[1].

Reuters reported that the Trump administration has reached drug-pricing agreements with more than 20 pharmaceutical companies ^[2]. Under Eli Lilly's deal, the Zepbound multidose pen is available at $299 a month at its lowest dose, with higher doses priced up to $449, and Foundayo starts at $149 a month through LillyDirect ^[2]. Novo Nordisk's agreement lowers Ozempic and Wegovy from about $1,000 and $1,350 a month to $350 through TrumpRx, Reuters reported ^[2]. That $350 figure is close to, but not the same as, the $349 listed on manufacturer pages for Wegovy self-pay after the starter period ^[1].

Why it matters for patients

Self-pay prices are what people pay when they have no commercial coverage for these drugs, when a plan excludes them, or when a deductible has not been met. The recorded Zepbound parity means the format itself no longer changes the cash price: a KwikPen and a single-dose vial cost the same at each dose, provided the refill arrives within 45 days ^[1]. Miss that window and the price moves back toward the $599 to $1,049 range ^[1].

The Foundayo discounts at 2.5 mg and 5.5 mg are temporary. They run through December 31, 2026, and the company has not disclosed what those doses will cost afterward ^[1].

For Medicare Part D members, the GLP-1 Bridge charges a flat $50 per 30-day fill for the Wegovy pen and pill, the Zepbound KwikPen and Foundayo ^[1]. Zepbound vials and single-dose pens are not covered by the Bridge, so the $299 self-pay vial price is not available through it ^[1]. Coupons and discount cards cannot be stacked on the Bridge copay, and that $50 does not count toward the Part D out-of-pocket cap ^[1]. With commercial insurance and a savings card, the lowest listed price is $25 a month ^[1].

Whether the pen-and-vial parity is permanent has not been reported; the September 2 review records one point in time ^[1].

What happens next

Zepbound returns to CVS Caremark's commercial formulary on October 1, 2026 ^[1]. On December 31, 2026, Foundayo's temporary prices for the 2.5 mg and 5.5 mg doses end, and Novo's window closes for prescriptions received for the $199 two-fill Wegovy starter offer; those prescriptions must ship by January 31, 2027 ^[1]. The FDA's proposed rule removing semaglutide, tirzepatide and liraglutide from the 503B bulks list had no final rule as of September 2 ^[1].